logo-loader
view4D pharma PLC

4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company.

Peyton says the merger will accelerate and de-risk 4D's admission to NASDAQ while providing immediate access to additional funds to support the group's pipeline of therapies. He adds it also will likely increase interest from US healthcare investors provide access to a much larger pool of specialist capital.

Quick facts: 4D pharma PLC

Price: 95.6 GBX

LSE:DDDD
Market: LSE
Market Cap: £125.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

4d pharma reveal positive data from phase II trial of treatment for...

4D pharma plc's (LON:DDD) Alex Stevenson speaks to Proactive London's Katie Pilbeam about the company's latest report which showed positive data for its phase II trial of its live biotherapeutic for irritable bowel syndrome (IBS). He says the results provide the foundation for continued...

on 7/10/20

2 min read